Open Access

KRAS Promoter Methylation Status and miR-18a-3p and miR-143 Expression in Patients With Wild-type KRAS Gene in Colorectal Cancer


1Cancer Biology Research Group, National Cancer Institute, Bogotá, Colombia

2Master’s Program in Human Genetics, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia

3Department of Pathology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia

4Clinical, Molecular and Cellular Radiobiology Research Group, National Cancer Institute, Bogotá, Colombia

5Oncological Pathology Group, National Cancer Institute, Bogotá, Colombia

6Public Health and Cancer Epidemiology Group, National Cancer Institute, Bogotá, Colombia

7Chemistry Department, Faculty of Sciences, Universidad Nacional de Colombia, Bogotá, Colombia

Cancer Diagnosis & Prognosis Sep-Oct; 2(5): 576-584 DOI: 10.21873/cdp.10145
Received 10 June 2022 | Revised 25 May 2024 | Accepted 25 July 2022
Corresponding author
Dr. M. Serrano, Instituto Nacional de Cancerología, Grupo de Investigación en Biología del Cáncer, Subdirección de Investigaciones, Calle 1ª No 9-85, Bogotá, Colombia. Tel: +601 3905012 Ext. 4203 and Dr. P. Moreno Acosta, Instituto Nacional de Cancerología, Grupo de Investigacion en Biologia del Cáncer, Grupo de Investigación en Radiobiología Clínica, Molecular y Celular, Subdirección de Investigaciones, Calle 1ª No 9-85, Bogotá, Colombia. Tel: +601 3905012 Ext. 4203, 406,


Background/Aim: Although some mutations of KRAS proto-oncogene, GTPase (KRAS) have been associated with the prognosis and therapeutic management of colorectal cancer (CRC), the epigenetic mechanisms (DNA methylation and microRNA expression) that regulate wild-type KRAS expression in patients with CRC are poorly known. The aim of this study was to establish whether there is a relationship between the expression of the wild-type KRAS gene, the methylation status of its distal promoter, and miR-143 and miR-18a-3p levels in samples of sporadic CRC. Patients and Methods: A total of 51 cases of sporadic CRC with wild-type KRAS were analyzed. The expression levels of KRAS mRNA, miR-18a-3p, miR-143, and KRAS protein, as well as methylation in the distal promoter of the KRAS gene were evaluated. Results: In the analyzed cases, KRAS mRNA expression was detected in 51.1%; wild-type KRAS protein was found in the membrane in 31.4% and in the cytoplasm in 98% of cases. An inverse relationship of marginal significance was observed between miR-18a-3p and KRAS protein expression in the cytoplasm (odds ratio=0.14, 95% confidence interval=0.012-1.092; p=0.08). The methylation status of the distal promoter of KRAS at four CpG islands was analyzed in 30 cases (58.8%): partial methylation of the four CpG islands evaluated was observed in two cases (6.7%). In these cases, KRAS protein expression was not evidenced at the membrane level; miR-18a-3p expression was not detected either but high expression of miR-143 was observed. Conclusion: No association was found between the expression levels of KRAS mRNA, miR-18a-3p, miR-143 and methylation status. Methylation status was detected with low frequency, thus being the first report of methylation in wild-type KRAS.
Keywords: KRAS, miR-18a-3p, miR-143, DNA methylation, Colorectal cancer

Colorectal cancer (CRC) ranks third in incidence and fourth in cancer mortality globally (1). Most of the studies on CRC have focused on genetics and the genetic alterations of genes, such as KRAS proto-oncogene, GTPase (KRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), adenomatous polyposis coli (APC), tumor protein 53 (p53) or phosphatase and tensin homolog (PTEN), among others, as well as their effects on molecular pathways, such as phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K)/PTEN/ serine/threonine kinase 1 (AKT) and Rat sarcoma (RAS) gene family/rapidly accelerated fibrosarcoma (RAF) gene family/mitogen-activated protein kinase (MEK) gene family/ extracellular-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), that lead to the development of CRC (2-4). In particular, the KRAS gene has been identified as a proto-oncogene activated by point mutations in more than 40% of CRC cases (5); its mutational status has been associated with a worse disease prognosis and lower response to treatments, such as immunotherapy (6). Nevertheless, patients wild-type KRAS gene also have a low response to treatments such as cetuximab (26-41%) or panitumumab (11-17%) (5). Knowing the methylation status as well as other epigenetic modifications associated with proto-oncogenes might offer new information contributing to the development of new therapeutic strategies in CRC, given that these modifications are reversible and that there are currently drugs that re-establish the function of these genes and thus improve the response to conventional treatments such as chemotherapy or radiotherapy (7,8). However, little is known about epigenetic modifications in wild-type proto-oncogenes.

The KRAS protein is a GTPase whose function is the transduction of signals that activate signaling cascades, such as PI3K, MAPK and T-cell lymphoma invasion and metastasis-inducing factor 1 (TIAM1), which cause cell proliferation and survival due to evasion of apoptosis and activate metabolism and cell growth, migration, and invasion (9). The role of wild-type KRAS protein in CRC is unknown; it is also unknown whether protein overexpression may have a similar effect to gene mutation, by promoting tumor progression. Regarding the regulation of KRAS gene expression, its distal promoter is involved in the transcription of the gene (10), and presents a large number of CpG islands and has several regions for anchoring specificity protein 1 (Sp1) and neurofibromin 1 (NF1) protein, associated with transcription initiation complexes (10,11). There are also microRNAs (miRNAs), such as miR-18a-3p and miR-143, in which a direct interaction with KRAS mRNA has been demonstrated by it binding to the 3’-untranslated region end of the mRNA, leading to its degradation or prevention of the translation process (12,13). The relationship of these miRNAs to the KRAS gene has been extensively studied (12-18).

This study aimed to determine whether there is a relationship between the expression of the wild-type KRAS gene (mRNA and protein), methylation of the distal promoter of this gene, and miR-143 and miR-18a-3p levels in formalin-fixed and paraffin-embedded tissues (FFPE) from patients with sporadic CRC. Information that allows determining whether epigenetic factors such as DNA methylation or miRNAs regulate the expression of wild-type KRAS may have important implications in understanding its role in the mechanism of CRC carcinogenesis, as well as possible applications in the prevention, diagnosis, or treatment of this type of cancer.

Patients and Methods

Definition of study subjects. This study included FFPE tissue blocks from 51 patients with sporadic CRC and wild-type KRAS gene who were treated at the gastroenterology service of the National Cancer Institute, Bogotá, Colombia between 2008 and 2015.

The amplification and detection of mutations in the KRAS gene was initially carried out using a Therascreen® KRAS RGQ PCR Kit (Qiagen, Hilden, Germany) and subsequently using Cobas® KRAS mutation test (Roche, Basel, Switzerland). For both kits, a Cobas z 480 analyzer (Roche) was used, following manufacturer instructions. FFPE tissue samples from three patients with CRC with KRAS mutations in codons 12 and 13 were used as reference.

DNA/RNA extraction and quantification. Extraction of genomic DNA and total RNA was performed by manual microdissection technique and 2-mm diameter punch of the tumor regions of the FFPE tissues selected by two pathologists, without including non-tumor tissue, using AllPrep DNA/RNA FFPE Kit (Qiagen), following the instructions given by the manufacturer. The extracted nucleic acids were quantified using Qubit RNA HS Assay, Qubit RNA BR Assay, Qubit DNA BR Assay, and Qubit DNA HS Assay Kits (Thermo Fisher Scientific-Invitrogen, Waltham, MA, USA), following manufacturer protocols.

KRAS mRNA expression levels. The expression levels of wild-type KRAS mRNA were determined by reverse transcriptase-quantification polymerase chain reaction (qPCR) with commercial KAPA SYBR® FAST One-Step qRT-PCR Master Mix (2X) Kit (Kapa Biosystems, Wilmington, MA, USA) on a LightCycler 480 II platform (Roche), following manufacturer indications and using previously described primers for KRAS (19) and ubiquitin C (UBC) (20) as a reference gene. Absolute copy number quantification was performed.

Expression of miR-18a-3p and miR-143. For this analysis, miRNAs were retrotranscribed using miScript II RT Kit (Qiagen). Quantification was performed by real-time PCR using miScript SYBR Green PCR Kit (Qiagen) and specific primers obtained from the miScript Primer Assays Kit (Qiagen) for miR-18a-3p, miR-143, and small nucleolar RNA, C/D box 61 (SNORD61) as reference gene, on the LightCycler 480 II platform (Roche), following the manufacturer indications. Absolute copy number quantification was performed.

Wild-type KRAS protein expression. KRAS protein expression was evaluated by immunohistochemistry (IHC). The tissues were blocked by 0.3% hydrogen peroxide and incubated for 20 min at 37˚C with rabbit polyclonal antibody to KRAS (HPA049830; Atlas Antibodies, Voltavägen, Bromma, Sweden) dilution 1:20 in phosphate-buffered saline. The primary antibody was identified using UltraView Universal DAB Detection Kit (Ventana Medical Systems, Inc.). Immunodetection was carried out with diaminobenzidine, while counterstaining was performed with hematoxylin, followed the Ventana automated procedure (Roche).

IHC evaluation. The presence/absence of cells staining for KRAS in the cell membrane and in the cytoplasm; the intensity of staining (weak, moderate, or intense); and the percentage of cells staining in the observed tissue were assigned values between 0% and 100%. For the analysis of protein expression, an IHC score was generated, both for membranous and the cytoplasmic expression, resulting from multiplying the staining percentage score by the score for staining intensity (weak=1, moderate=2, or intense=3). Normal colon mucosa was used as positive staining control.

Methylation analysis of the distal promoter of the KRAS gene. Bisulfite conversion of the DNA, PCR amplifications of the distal promoter of the KRAS gene and amplimer sequencing were performed as previously described (21,22). The sequences obtained were aligned against the reference sequence (GenBank: X07536.1), using the free CLC Sequence Viewer software (version 8.0) (CLC Bio-Qiagen, Aarhus, Denmark).

Statistical analysis. The results obtained were treated as categorical variables. Frequency tables were constructed and based on data distribution, analysis groups were established and subsequently used to find possible associations between the variables analyzed in this study using Fisher’s exact test. The following categorical variables were considered: Normalized KRAS mRNA expression (absent/low: <0.01 and high: ≥0.01); normalized miR-18a-3p expression (absent or present); normalized miR-143 expression level (absent/low: <0.01 and high: ≥0.01); KRAS protein level evaluated as IHC score: absent or low: ≤10 in membrane and ≤100 in cytoplasm; and high: >10 in membrane and >100 in cytoplasm); methylation level in one or more of the four CpG islands evaluated in the distal promoter of the KRAS gene. Additionally, multivariate analyses were performed to determine the strength of association between the selected variables. For these, missing data were discarded; consequently, analyses were performed for death from 41 patients. The variable ‘stage’ was re-categorized into early (stage I and II: T1N0M0 to T4bN0M0) and advanced (stage III and IV: T1N1M0 - any T, any N, M1c) (23). A significance level of α<0.05 and a marginal significance of α<0.1 were established for all variables. Data were analyzed using R-Project software (version 4.0.3).


Baseline status. The mutational status for the KRAS gene, codons 12 and 13, was evaluated in 51 patients and none were revealed to have mutations in these codons. The demographic and clinicopathological characteristics of the patients included in this study are presented in Table I.

Expression of wild-type KRAS mRNA. In four cases (7.8%), it was not possible to determine KRAS mRNA expression since there was no expression of UBC. These cases were excluded from subsequent analyses (Table I). Based on the observed data, three categories were constructed for KRAS mRNA expression levels to facilitate subsequent analyses: Absent: 23 cases (48.94%); low level (values <0.01): 8 cases (17.02%); and high level (values ≥0.01): 16 cases (34.04%) (Table I).

Expression of miR-143 and miR-18a-3p. Considering the expression level distributions for miR-18a-3p, data were categorized as expression absent and present, while for miR-143, data were categorized as low or absent (Table I). Expression levels were different for each analyzed miRNA; 64.7% of cases did not express miR-18a-3p, whereas only 19.6% of cases did not express miR-143.

Expression of wild-type KRAS protein. The immunoreactivity to the KRAS antibody observed in one of the cases used in this study in the membrane and in the cytoplasm is illustrated in Figure 1. Wild-type KRAS protein was most frequently expressed in cytoplasm (98.4%) in comparison to the membrane (31.4%) (Table I). Regarding the IHC score, in most cases, scores represented absent or low KRAS expression (Table I).

Correlation between KRAS mRNA and protein expression levels. No statistically significant associations were found between KRAS mRNA expression category (absent, low, and high) and the IHC score for KRAS protein expression in the membrane (p=0.08) and the cytoplasm (p=0.79).

Correlation between wild-type KRAS expression and miR-18a-3p and miR-143 expression. No correlation was found between KRAS mRNA expression and miR-18a-3p or miR-143 expression, miR-18a-3p and protein expression in the membrane and the cytoplasm, nor miR-143 expression and protein levels in the cytoplasm measured as IHC score in the univariate or multivariate analyses, including other variables (age, sex, degree of differentiation, and stage). When performing logistic regression, categorizing by clinical variables, IHC score and miRNA expression, no statistically significant association was found between miR-18a-3p and KRAS protein expression in the cytoplasm or the membrane. There was no statistically significant relationship between miR-143 and cytoplasmic or membranous KRAS expression (data not shown).

Methylation of the distal promoter of the KRAS gene. Methylation status was analyzed in 30 cases. In 28 of these (93.3%), no methylation was detected in any of the CpG islands in the analyzed region (Figure 2A), whereas in two cases (6.7%), partial methylation was detected in some of the CpG islands evaluated (Figure 2B and C). In the two cases with partial methylation in the promoter region of the wild-type KRAS gene, no membranous expression of KRAS protein was detected, while high cytoplasmic KRAS protein expression was found (IHC scores were 180 and 200, respectively). In these two cases, KRAS mRNA expression was low, miR-18a-3p expression was absent, while miR-143 expression was high.


This study highlights novel information on the methylation status of the distal promoter of the wild-type KRAS gene, the expression of the protein at the cellular level and how it relates to the expression of two miRNAs whose direct targets are the wild-type KRAS gene.

By qPCR analysis, 51 patients with a diagnosis of CRC who did not have mutations in the KRAS gene at codons 12 and 13 were selected. However, mutations at codons 61 and 146 were not taken into account due to their low frequency (24). It is important to consider that despite the sensitivity of qPCR in the diagnosis of KRAS gene mutations, detection is limited by the cellular heterogeneity present in the tumor, the region from which the sample is extracted, and the integrity of the DNA used to perform the analysis, given that in most cases samples from FFPE tissues are used (25). Therefore, it is possible that there were cell subpopulations that may have had mutations in the KRAS gene and were not detected (26).

In this study, expression of KRAS protein in the cytoplasm was higher than that in the membrane. In other studies of CRC, KRAS expression has been reported with highly variable values, between 16% and 100% in the membrane (27-29) and between 42% and 100% in the cytoplasm (29-33), which is probably due to the lack of unified criteria that would allow comparisons between them and the different types of antibodies used in each study compared to ours. Contrary to what was observed in the present study, some studies have reported higher KRAS protein expression in the membrane than in the cytoplasm (28,32), which may be caused by KRAS ‘turnover’ mediated by endosomes from the endoplasmic reticulum, which might contain a higher proportion of KRAS not yet available at the membrane level (34). In turn, these proportions may vary between the analyzed samples. It is important to consider that these studies do not mention whether the patients analyzed had mutations in the KRAS gene, a fact that might have an impact on the cellular location of the protein, given that in mutational states, the protein is constitutively active in membrane signal transduction. Another possible cause of these discrepancies may be the lack of specificity of our antibody for the KRAS protein (34,35), given that the antibody used in this study also recognizes HRAS and NRAS, which might lead to overestimation in the IHC results obtained.

Interestingly, The Human Protein Atlas shows that KRAS protein expression in normal colon tissue using the antibody used in the present study is 100%, with an intense staining pattern, while in CRC samples, a 75% positivity and different staining intensities are reported, which indicates that KRAS protein expression decreases during carcinogenesis (36). It has also been reported that KRAS mutation does not alter the expression level or subcellular localization of KRAS protein (28). Although the overexpression of the wild-type KRAS gene can be considered a mechanism comparable to a gain-of-function due to mutations, the high expression of wild-type KRAS protein in normal tissue rules out the possibility that an increase in its expression has a similar effect to that of activating mutations and suggests opposite effects given its decrease during tumor progression. Some studies conducted in murine and in vitro models demonstrated the role of wild-type KRAS as a tumor-suppressor gene in the lung (37) and in the colon and rectum (38,39). These data suggest that wild-type KRAS protein has tumor-suppressive activity, which is frequently lost during tumor progression (37,38,40,41).

No statistically significant association was found between KRAS mRNA and protein expression levels in the membrane and the cytoplasm, which is in agreement with what was reported by Chen et al. (12) and the information given by the producer of the antibody used in this study ( Lack of correlation may be explained by considering that mRNA is very labile, and it is possible that part of the nucleic acid is degraded during its extraction. These results may also be affected by the stability of both mRNA and proteins, which is regulated by mechanisms not evaluated in this study, such as post-transcriptional mRNA methylation, post-translational modifications of proteins, among others (42-46).

Regarding miR-18a-3p expression, the frequency of positive patients (35.3%) in our study is lower than previously reported for this miRNA, with expression levels between 77% and 92% in FFPE tumor tissues and in fresh CRC tissue samples, respectively (18,46,47). It is important to consider that this study used FFPE material collected between 2008 and 2015 for RNA extraction, a fact that may have some impact on the results obtained due to the instability of the RNA extracted from these tissues, even though miRNAs are considered more stable than mRNA due to their size. In this study, no significant association was found between the expression levels of miR-18a-3p and KRAS mRNA.

Regarding miR-143, the expression found in this study was similar to other studies in which low values between 57% and 88% or absence have been reported (14-17,48-51). Evidence suggests that a decrease in miR-143 in CRC is independent of the transcription process, and it was hypothesized that this might be due to reduced Dicer-processing activity or to reduced miRNA stability, possibly as a result of diminished retention in a ribonucleoprotein complex (49).

Recently, a study was published evaluating the expression levels of this miRNA in samples from patients diagnosed with CRC, but without mutations in the KRAS gene, in which no significant differences were observed between the expression levels of this miRNA and normal tissue adjacent to the tumor (52), a fact that is contradictory to several studies showing the role of this miRNA with miR-145 in tumor suppression (53).

No significant association was found between the expression of miR-143 and KRAS mRNA or protein. On the contrary, other studies of patients diagnosed with CRC and of colon adenocarcinoma cell lines have determined an inverse correlation between KRAS protein and miR-143 expression levels (12), but to our knowledge, there are no studies on patient samples with which the results of our study can be compared.

The distal promoter region in which the methylation analysis was carried out is an anchoring site for the transcription factor Sp1, which has a preponderant role in the transcription of the RAS genes (11,54,55). In this study, a low frequency of partial methylation was observed, which would be consistent with the high expression of KRAS protein. The low methylation frequencies observed in this study may be related to the type of sample analyzed, since the integrity of DNA may be affected by long exposure to formaldehyde and the low pH to which the sample is subjected for preservation. In future studies, it would be interesting to apply sample restoration methods that have been shown to be effective in improving DNA quality for subsequent molecular applications (56). Another explanation may be the detection limit reported in the literature for direct sequencing, which is approximately 10 to 20%, and if heterogeneous methylation exists in the tissue, methylated variants below this level would not be detected with the described methodology (57). The low number of cases with methylation did not allow evaluation of whether partial methylation in the analyzed CpG islands affects the expression of the KRAS gene at the mRNA and protein levels. However, the partial methylation in the CpG regions evaluated in the distal promoter of KRAS is of interest since it might be assumed that methylation, being a reversible event, occurs during some phases in the progression of the disease and is then reversed in most cases. However, in a few cases, partial methylations in the gene promoter would be retained. If so, it would be interesting to determine what the function of these partial methylations is and what impact they have on disease progression and treatment.


No association was found between the expression levels of KRAS mRNA, miR-18a-3p, miR-143 and methylation status. Methylation status was detected with low frequency, thus being the first report of methylation in wild-type KRAS.

Conflicts of Interest

The Authors declare that they have no competing interests.

Authors’ Contributions

All Authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Jehison Alirio Herrera-Pulido, Orlando Ricaurte Guerrero, Jinneth Acosta Forero, Pablo Moreno-Acosta, Alfredo Romero, Carolina Sanabria, Gustavo Hernández, and Martha Lucía Serrano. The first draft of the article was written by Jehison Alirio Herrera-Pulido and Martha Lucía Serrano and all Authors commented on previous versions of the article. All Authors read and approved the final article.


The Authors express their deepest gratitude to Dr. Miguel López and Dr. Humberto Arboleda for all their contributions during the development of this study; to Dr. Hernán Hernández for his valuable contributions to the construction of primers used in this study; to Marcela Nuñez for carrying out the statistical analyses; and to the National Cancer Institute of Colombia for providing physical spaces and financial resources to carry out this research.


1 Arnold M Sierra MS Laversanne M Soerjomataram I Jemal A & Bray F Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66(4) 683 - 691 2017. PMID: 26818619. DOI: 10.1136/gutjnl-2015-310912
2 Markowitz SD & Bertagnolli MM Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 361(25) 2449 - 2460 2009. PMID: 20018966. DOI: 10.1056/NEJMra0804588
3 Lv J Liu H Su J Wu X Liu H Li B Xiao X Wang F Wu Q & Zhang Y DiseaseMeth: a human disease methylation database. Nucleic Acids Res. 40(Database issue) D1030 - D1035 2012. PMID: 22135302. DOI: 10.1093/nar/gkr1169
4 Zhang C Zhao H Li J Liu H Wang F Wei Y Su J Zhang D Liu T & Zhang Y The identification of specific methylation patterns across different cancers. PLoS One. 10(3) e0120361 2015. PMID: 25774687. DOI: 10.1371/journal.pone.0120361
5 Vaughn CP Zobell SD Furtado LV Baker CL & Samowitz WS Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 50(5) 307 - 312 2011. PMID: 21305640. DOI: 10.1002/gcc.20854
6 Hänggi K & Ruffell B Oncogenic KRAS drives immune suppression in colorectal cancer. Cancer Cell. 35(4) 535 - 537 2019. PMID: 30991021. DOI: 10.1016/j.ccell.2019.03.008
7 Vaiopoulos AG Athanasoula KCh & Papavassiliou AG Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim Biophys Acta. 1842(7) 971 - 980 2014. PMID: 24561654. DOI: 10.1016/j.bbadis.2014.02.006
8 Yan W & Guo M Epigenetics of colorectal cancer. Methods in Molecular Biology. 1238 405 - 424 2014. DOI: 10.1007/978-1-4939-1804-1_22
9 Gimple RC & Wang X RAS: Striking at the core of the oncogenic circuitry. Front Oncol. 9 965 2019. PMID: 31681559. DOI: 10.3389/fonc.2019.00965
10 Jordano J & Perucho M Initial characterization of a potential transcriptional enhancer for the human c-K-ras gene. Oncogene. 2(4) 359 - 366 1988. PMID: 3283654.
Pubmed |
11 Yamamoto F & Perucho M Characterization of the human c-K-ras gene promoter. Oncogene Res. 3(2) 125 - 130 1988. PMID: 3067187.
Pubmed |
12 Chen X Guo X Zhang H Xiang Y Chen J Yin Y Cai X Wang K Wang G Ba Y Zhu L Wang J Yang R Zhang Y Ren Z Zen K Zhang J & Zhang CY Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 28(10) 1385 - 1392 2009. PMID: 19137007. DOI: 10.1038/onc.2008.474
13 Tsang WP & Kwok TT The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 30(6) 953 - 959 2009. PMID: 19372139. DOI: 10.1093/carcin/bgp094
14 Slaby O Svoboda M Fabian P Smerdova T Knoflickova D Bednarikova M Nenutil R & Vyzula R Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 72(5-6) 397 - 402 2007. PMID: 18196926. DOI: 10.1159/000113489
15 Akao Y Nakagawa Y & Naoe T MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 16(4) 845 - 850 2006. PMID: 16969504.
Pubmed |
16 Wang CJ Zhou ZG Wang L Yang L Zhou B Gu J Chen HY & Sun XF Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers. 26(1) 27 - 34 2009. PMID: 19242066. DOI: 10.3233/DMA-2009-0601
17 Pekow J Meckel K Dougherty U Butun F Mustafi R Lim J Crofton C Chen X Joseph L & Bissonnette M Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. Am J Physiol Gastrointest Liver Physiol. 308(3) G179 - G187 2015. PMID: 25477374. DOI: 10.1152/ajpgi.00208.2014
18 Yau TO Wu CW Dong Y Tang CM Ng SS Chan FK Sung JJ & Yu J microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer. 111(9) 1765 - 1771 2014. PMID: 25233396. DOI: 10.1038/bjc.2014.484
19 Cepero V Sierra JR Corso S Ghiso E Casorzo L Perera T Comoglio PM & Giordano S MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 70(19) 7580 - 7590 2010. PMID: 20841479. DOI: 10.1158/0008-5472.CAN-10-0436
20 Vandesompele J De Preter K Pattyn F Poppe B Van Roy N De Paepe A & Speleman F Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3(7) RESEARCH0034 2002. PMID: 12184808. DOI: 10.1186/gb-2002-3-7-research0034
21 Herrera-Pulido J Segura-Moreno YY Montero-Ovalle WJ Medina-Boada VL Moreno-Acosta P Romero-Rojas AE & Serrano- López ML Evaluation of DNA methylation in formalin-fixed, paraffin embedded colorectal cancer tissues (FFPE). Rev Colomb Cancerol. 25(2) 110 - 114 2021. DOI: 10.35509/01239015.704
22 Parrish RR Day JJ & Lubin FD Direct bisulfite sequencing for examination of DNA methylation with gene and nucleotide resolution from brain tissues. Curr Protoc Neurosci. Chapter 7 Unit 7.24 2012. PMID: 22752896. DOI: 10.1002/0471142301.ns0724s60
23 Jessup JM Goldberg RM Asare EA Benson AB Brierley JD Chang GJ Chen V Compton CC De Nardi P Goodman KA Gress D Guinney J Gunderson LL Hamilton SR Hanna NN Kakar S Kosinski LA Negoita S Ogino S Overman MJ Quirke P Rohren E Sargent DJ Schumacher-Penberthy lt Shibata D Sinicrope FA Steele SR Stojadinovic A Tejpar S Weiser MR Welton ML & Washington MK Colon and Rectum. In: AJCC Cancer Staging Manual, Eighth Edition. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM and Meyer LR (eds.). New York, NY, Springer. pp. 251 2017.
24 Meng M Zhong K Jiang T Liu Z Kwan HY & Su T The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother. 140 111717 2021. PMID: 34044280. DOI: 10.1016/j.biopha.2021.111717
25 Jancík S Drábek J Radzioch D & Hajdúch M Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010 150960 2010. PMID: 20617134. DOI: 10.1155/2010/150960
26 Parsons BL & Myers MB Personalized cancer treatment and the myth of KRAS wild-type colon tumors. Discov Med. 15(83) 259 - 267 2013. PMID: 23636143.
Pubmed |
27 Ines C Donia O Rahma B Ben Ammar A Sameh A Khalfallah T Abdelmajid BH Sabeh M & Saadia B Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort. Tumour Biol. 35(7) 7163 - 7175 2014. PMID: 24763823. DOI: 10.1007/s13277-014-1874-4
28 Wan XB Wang AQ Cao J Dong ZC Li N Yang S Sun MM Li Z & Luo SX Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World J Gastroenterol. 25(7) 808 - 823 2019. PMID: 30809081. DOI: 10.3748/wjg.v25.i7.808
29 Bai S Feng Q Pan XY Zou H Chen HB Wang P Zhou XL Hong YL Song SL & Yang JL Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer. Int J Mol Med. 39(4) 861 - 868 2017. PMID: 28259994. DOI: 10.3892/ijmm.2017.2903
30 Elsabah MT & Adel I Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J Egypt Natl Canc Inst. 25(1) 51 - 56 2013. PMID: 23499207. DOI: 10.1016/j.jnci.2013.01.003
31 Akkiprik M Celikel CA Düşünceli F Sönmez O Güllüoğlu BM Sav A & Ozer A Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients. Turk J Gastroenterol. 19(1) 22 - 27 2008. PMID: 18386236.
Pubmed |
32 Sammoud S Khiari M Semeh A Amine L Ines C Amira A Lilia K Taher K Sabeh M & Saadia B Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia. Appl Immunohistochem Mol Morphol. 20(2) 146 - 152 2012. PMID: 21768877. DOI: 10.1097/PAI.0b013e3182240de1
33 Malhotra P Anwar M Nanda N Kochhar R Wig JD Vaiphei K & Mahmood S Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol. 34(3) 1901 - 1911 2013. PMID: 23526092. DOI: 10.1007/s13277-013-0734-y
34 Schmick M Vartak N Papke B Kovacevic M Truxius DC Rossmannek L & Bastiaens PIH KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell. 157(2) 459 - 471 2014. PMID: 24725411. DOI: 10.1016/j.cell.2014.02.051
35 Gry M Rimini R Strömberg S Asplund A Pontén F Uhlén M & Nilsson P Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics. 10 365 2009. PMID: 19660143. DOI: 10.1186/1471-2164-10-365
36 Uhlen M Oksvold P Fagerberg L Lundberg E Jonasson K Forsberg M Zwahlen M Kampf C Wester K Hober S Wernerus H Björling L & Ponten F Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 28(12) 1248 - 1250 2010. PMID: 21139605. DOI: 10.1038/nbt1210-1248
37 Zhang Z Wang Y Vikis HG Johnson L Liu G Li J Anderson MW Sills RC Hong HL Devereux TR Jacks T Guan KL & You M Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 29(1) 25 - 33 2001. PMID: 11528387. DOI: 10.1038/ng721
38 Luo F Poulogiannis G Ye H Hamoudi R Dong G Zhang W Ibrahim AE & Arends MJ Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation. Int J Exp Pathol. 95(1) 8 - 15 2014. PMID: 24354449. DOI: 10.1111/iep.12064
39 Li H Cao HF Wan J Li Y Zhu ML & Zhao P Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line. World J Gastroenterol. 13(6) 934 - 938 2007. PMID: 17352027. DOI: 10.3748/wjg.v13.i6.934
40 Pfeifer GP A new verdict for an old convict. Nat Genet. 29(1) 3 - 4 2001. PMID: 11528376. DOI: 10.1038/ng0901-3
41 To MD Rosario RD Westcott PM Banta KL & Balmain A Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene. 32(34) 4028 - 4033 2013. PMID: 22945650. DOI: 10.1038/onc.2012.404
42 Perl K Ushakov K Pozniak Y Yizhar-Barnea O Bhonker Y Shivatzki S Geiger T Avraham KB & Shamir R Reduced changes in protein compared to mRNA levels across non-proliferating tissues. BMC Genomics. 18(1) 305 2017. PMID: 28420336. DOI: 10.1186/s12864-017-3683-9
43 Greenbaum D Colangelo C Williams K & Gerstein M Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 4(9) 117 2003. PMID: 12952525. DOI: 10.1186/gb-2003-4-9-117
44 Roost C Lynch SR Batista PJ Qu K Chang HY & Kool ET Structure and thermodynamics of N6-methyladenosine in RNA: a spring-loaded base modification. J Am Chem Soc. 137(5) 2107 - 2115 2015. PMID: 25611135. DOI: 10.1021/ja513080v
45 Zhao BS Roundtree IA & He C Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 18(1) 31 - 42 2017. PMID: 27808276. DOI: 10.1038/nrm.2016.132
46 Alvarado ME & Wasserman M Analysis of phosphorylated proteins and inhibition of kinase activity during Giardia intestinalis excystation. Parasitol Int. 59(1) 54 - 61 2010. PMID: 19861170. DOI: 10.1016/j.parint.2009.10.005
47 Brunet Vega A Pericay C Moya I Ferrer A Dotor E Pisa A Casalots À Serra-Aracil X Oliva JC Ruiz A & Saigí E microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 30(1) 320 - 326 2013. PMID: 23673725. DOI: 10.3892/or.2013.2475
48 Kulda V Pesta M Topolcan O Liska V Treska V Sutnar A Rupert K Ludvikova M Babuska V Holubec L Jr & Cerny R Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet. 200(2) 154 - 160 2010. PMID: 20620599. DOI: 10.1016/j.cancergencyto.2010.04.015
49 Michael MZ O’ Connor SM van Holst Pellekaan NG Young GP & James RJ Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 1(12) 882 - 891 2003. PMID: 14573789.
Pubmed |
50 Pichler M Winter E Stotz M Eberhard K Samonigg H Lax S & Hoefler G Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer. 106(11) 1826 - 1832 2012. PMID: 22549179. DOI: 10.1038/bjc.2012.175
51 Ng EK Tsang WP Ng SS Jin HC Yu J Li JJ Röcken C Ebert MP Kwok TT & Sung JJ MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer. 101(4) 699 - 706 2009. PMID: 19638978. DOI: 10.1038/sj.bjc.6605195
52 Fiala O Sorejs O Hosek P Liska V Vycital O Bruha J Kucera R Topolcan O Finek J Maceckova D & Pitule P Association of miR-125b, miR-17 and let-7c dysregulations with response to anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Cancer Genomics Proteomics. 17(5) 605 - 613 2020. PMID: 32859639. DOI: 10.21873/cgp.20217
53 Cui SY Wang R & Chen LB MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 18(10) 1913 - 1926 2014. PMID: 25124875. DOI: 10.1111/jcmm.12358
54 Ishii S Merlino GT & Pastan I Promoter region of the human Harvey ras proto-oncogene: similarity to the EGF receptor proto-oncogene promoter. Science. 230(4732) 1378 - 1381 1985. PMID: 2999983. DOI: 10.1126/science.2999983
55 Ishii S Kadonaga JT Tjian R Brady JN Merlino GT & Pastan I Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter. Science. 232(4756) 1410 - 1413 1986. PMID: 3012774. DOI: 10.1126/science.3012774
56 Dumenil TD Wockner LF Bettington M McKeone DM Klein K Bowdler LM Montgomery GW Leggett BA & Whitehall VL Genome-wide DNA methylation analysis of formalin-fixed paraffin embedded colorectal cancer tissue. Genes Chromosomes Cancer. 53(7) 537 - 548 2014. PMID: 24677610. DOI: 10.1002/gcc.22164
57 Do H & Dobrovic A Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer. 8 82 2009. PMID: 19811662. DOI: 10.1186/1476-4598-8-82